Clinical breast cancer最新文献

{"title":"Clinicopathologic Features and Digital Imaging Analysis of HER2 Protein in Breast Carcinomas With Different HER2 Fluorescence in Situ Hybridization Patterns","authors":"Aidan C. Li ,&nbsp;Scott Hammond ,&nbsp;Debra Crosby ,&nbsp;Zaibo Li ,&nbsp;Anil V. Parwani","doi":"10.1016/j.clbc.2024.10.004","DOIUrl":"10.1016/j.clbc.2024.10.004","url":null,"abstract":"<div><h3>Background</h3><div>HER2-targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer (BC), which represents 15% to 20% of all BC cases. HER2 status is assessed via immunohistochemistry (IHC) and/or in situ hybridization (ISH), dividing BCs into five groups (G1-G5).</div></div><div><h3>Patients and methods</h3><div>In a study of 2,702 primary BC cases, comprising 12.7% G1, 0.2% G2, 2.8% G3, 8.5% G4, and 75.9% G5, we analyzed clinicopathologic features and HER2 protein expression digitally for each ISH group.</div></div><div><h3>Results</h3><div>Notably, G5 cases had a higher proportion of lobular carcinoma (13.9%) compared to other groups. G3 cases showed the highest percentage of grade 3 tumors (56.9%), while G5 cases had the lowest (21.4%). Additionally, G5 cases had the highest rate of estrogen receptor (ER) positivity (84.6%), while G1-HC (high copy number) cases had the lowest (70.4%). Most G1-HC cases were HER2 IHC 3+ (76.1%), while most G5 cases were IHC 0/1+ (75.7%). IHC 2+ was most common in G1-LC (low copy number) and G3 cases (83.8% and 90.7%, respectively), with G4 cases predominantly IHC 2+ (56.3%) and IHC 1+ (30.1%). Discordant HER2 IHC and ISH results were observed in 12 cases (0.4%), including 7 G1-HC (2.3%), 4 G1-LC (10.8%), and 1 G5 case (0.1%). Digital quantification of HER2 IHC levels in all groups except G5 revealed that G1-HC tumors had the highest HER2 protein expression, followed by G3, with G4 showing the lowest.</div></div><div><h3>Conclusion</h3><div>These findings offer valuable insights into the clinicopathologic characteristics and future management for different HER2 ISH groups.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 38-45"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life Outcomes in Breast Cancer Patients Receiving Chemotherapy With or Without Radiation Therapy","authors":"Ryan T. Morse ,&nbsp;Nathan W. Bean ,&nbsp;Jacob Hall ,&nbsp;Allison Deal ,&nbsp;Kirsten A. Nyrop ,&nbsp;Yara Abdou ,&nbsp;Elizabeth C. Dees ,&nbsp;Emily M. Ray ,&nbsp;Trevor A. Jolly ,&nbsp;Katherine E. Reeder-Hayes ,&nbsp;Ellen Jones ,&nbsp;Gaorav P. Gupta ,&nbsp;Shekinah Elmore ,&nbsp;Hyman B. Muss ,&nbsp;Dana L. Casey","doi":"10.1016/j.clbc.2024.08.015","DOIUrl":"10.1016/j.clbc.2024.08.015","url":null,"abstract":"<div><h3>Purpose</h3><div>Understanding quality of life (QOL) implications of individual components of breast cancer treatment is important as systemic therapies continue to improve oncologic outcomes. We hypothesized that adjuvant radiation therapy does not significantly impact QOL domains in breast cancer patients undergoing chemotherapy.</div></div><div><h3>Methods</h3><div>Data was drawn from three prospective studies in women with localized breast cancer being treated with chemotherapy from March 2014 to December 2019. Patient-reported measures were collected at baseline (pretreatment) and post-treatment using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) measure, which consists of 5 subscales. Changes in mean QOL scores in patients who received radiotherapy were compared to those who did not using a one-sided noninferiority method. Statistical significance was determined below 0.05 to meet noninferiority.</div></div><div><h3>Results</h3><div>In a sample of 175 patients, 131 were treated with radiation and 44 had no radiation. The sample consisted mostly of stage I-II breast cancer (78%) with hormone receptor positive (59%) disease, receiving either neoadjuvant (36%) or adjuvant chemotherapy (64%). Mean change in QOL for the group treated with radiation compared to no radiation was noninferior with respect to Physical Well-Being (<em>P</em> = .0027), Social/Family Well-Being (<em>P</em> = .0002), Emotional Well-Being (<em>P</em> = .0203), FACIT-Fatigue Subscale (<em>P</em> = .0072), and the Total FACIT-F score (<em>P</em> = .0005); however, mean change in QOL did not meet noninferiority for Functional Well-Being (<em>P</em> = .0594).</div></div><div><h3>Conclusion</h3><div>Patient-reported QOL from baseline to post-treatment, using the Total FACIT-F score, was noninferior in patients treated with versus without radiation therapy. This finding, in addition to individualized QOL subscales, provides important information in the informed decision-making process when discussing the effects of locoregional radiation on QOL in localized breast cancer patients treated with chemotherapy.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e86-e93"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deintensification of Locoregional Therapy Following Neoadjuvant Chemotherapy for Breast Cancer: Where do We Go From Here?","authors":"Chirag Shah,&nbsp;Sheen Cherian","doi":"10.1016/j.clbc.2024.08.013","DOIUrl":"10.1016/j.clbc.2024.08.013","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e94-e95"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing and Comparing the Diagnostic Effectiveness of [18F]FDG PET/CT and [18F]FDG PET/MRI for Distant Metastases in Breast Cancer Patients With Invasive Lobular Carcinoma Histology: An Ongoing Topic of Debate?","authors":"Kadri Altundag","doi":"10.1016/j.clbc.2024.10.012","DOIUrl":"10.1016/j.clbc.2024.10.012","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Page e99"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective Strategies for the Prevention and Mitigation of Phosphatidylinositol-3-Kinase Inhibitor-Associated Hyperglycemia: Optimizing Patient Care","authors":"Heather N. Moore ,&nbsp;Marcus D. Goncalves ,&nbsp;Abigail M. Johnston ,&nbsp;Erica L. Mayer ,&nbsp;Hope S. Rugo ,&nbsp;William J. Gradishar ,&nbsp;Dylan M. Zylla ,&nbsp;Richard M. Bergenstal","doi":"10.1016/j.clbc.2024.09.017","DOIUrl":"10.1016/j.clbc.2024.09.017","url":null,"abstract":"<div><div>Hyperglycemia is a common adverse event (AE) associated with phosphatidylinositol-3-kinase inhibitors (PI3Kis) and considered an on-target effect. Presence of hyperglycemia is associated with poor outcomes in patients with cancer, and there is need for further refinement of hyperglycemia prevention and mitigation strategies in patients receiving PI3Kis. In this review, the authors highlight effective strategies for preventing PI3Ki-induced hyperglycemia before and during treatment as well as hyperglycemia management. Prior to initiating treatment with PI3Ki, identify baseline risk factors of patients at increased risk for developing hyperglycemia, which include older age, obesity, and glycosylated hemoglobin (HbA1c) 5.7%-6.4% (prediabetes or Type 2 diabetes). To prevent new-onset hyperglycemia, optimize blood glucose, and recommend a low-carbohydrate (60-130 g/day) diet along with regular exercise to all patients prior to initiating the PI3Ki. Prophylactic metformin may be considered in all patients starting a PI3Ki with HbA1c ≤6.4%. Although existing recommendations support monitoring fasting blood glucose (FBG) once weekly (twice-weekly for intermediate-risk, daily for high-risk patients) and HbA1c every 3 months upon initiation of PI3Ki, more frequent FBG monitoring may be considered for prompt detection of hyperglycemia. Experts also recommend considering postprandial glucose monitoring because it is an early indicator of glucose intolerance. If hyperglycemia develops, metformin (first-line) and/or sodium glucose co-transporter 2 inhibitors or thiazolidinediones (second-/third-line) are the preferred agents; consider early referral to an endocrinologist. In conclusion, hyperglycemia is a common but manageable AE associated with PI3Kis. Multidisciplinary approach to the prevention, monitoring, and management of hyperglycemia optimizes patient care and allows patients to maintain therapy on PI3Ki.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 1-11"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Prognostic Role of the PAM50 Signature and Selected Immune-Related Signatures for Recurrence in Patients With T1abN0 Breast Cancer","authors":"Christina M. S. Hassing ,&nbsp;Tove Holst Filtenborg Tvedskov ,&nbsp;Niels Kroman ,&nbsp;Ann Søegaard Knoop ,&nbsp;Anne-Vibeke Lænkholm","doi":"10.1016/j.clbc.2024.08.003","DOIUrl":"10.1016/j.clbc.2024.08.003","url":null,"abstract":"<div><h3>Background</h3><div>De-escalation of adjuvant treatment in patients with T1abN0 breast cancer is discussed internationally. Identification of new prognostic factors in these patients may assist this de-escalation. The PAM50 signature and tumor inflammation signature (TIS), Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) signatures are possible prognostic factors for recurrence.</div></div><div><h3>Materials and Methods</h3><div>Danish patients with T1abN0 breast cancer diagnosed between 2007-2016 were identified, the NanoString Breast Cancer 360 Panel was performed on tissue samples from cases with recurrence matched 1:1 with controls without recurrence (<em>n</em> = 234). The association between gene signatures and recurrence was analyzed with conditional logistic regression.</div></div><div><h3>Results</h3><div>Patients with the basal-like subtype had higher values of TIS, PD-1 and PD-L1 scores compared with other subtypes. Patients with higher PD-L1 score had significantly lower odds of recurrence (odds ratio [OR] 0.61, <em>P</em> = .01). Likewise, an increased TIS score was associated to lower, but nonsignificant odds of recurrence (OR 0.76, <em>P</em> = .07). Patients with human epidermal growth factor receptor 2 (HER2)-enriched subtype had significantly higher odds of recurrence compared with patients with luminal A subtype (OR 4.8, <em>P</em> = .03).</div></div><div><h3>Discussion</h3><div>PAM50 and immune-related signatures provide important prognostic information in patients with T1abN0 breast cancer, which may refine the risk assessment in these patients.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e71-e78.e2"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease","authors":"Sujan Niraula ,&nbsp;Sugam Gouli ,&nbsp;Andrea M. Baran ,&nbsp;Ruth O'Regan ,&nbsp;Haley Tyburski ,&nbsp;Huina Zhang ,&nbsp;Sara Hardy ,&nbsp;Nimish Mohile ,&nbsp;Carey K. Anders ,&nbsp;Ajay Dhakal","doi":"10.1016/j.clbc.2024.09.019","DOIUrl":"10.1016/j.clbc.2024.09.019","url":null,"abstract":"<div><h3>Background</h3><div>It is unclear whether breast cancer (BC) subtypes or CSF cytology results are associated with overall survival (OS) among patients with BC leptomeningeal disease (LMD). This single-institution retrospective study compares OS among BC patients with LMD across various breast cancer subtypes and CSF cytology results.</div></div><div><h3>Methodology</h3><div>The study enrolled BC patients diagnosed with LMD between 2010 and 2023. Breast cancer subtypes were classified as A. ER+/HER2-, HER2+, or triple-negative BC (TNBC); B. HER2+, HER2-Low, HER2-Zero. CSF cytology subtypes included CSF+, CSF-, or CSF not tested (NT). OS was summarized via Kaplan-Meier analysis and compared using log-rank test. Cox models were used for multivariate analyses.</div></div><div><h3>Results</h3><div>Out of 69 patients registered, median OS (95% CI) for ER+/HER2- (<em>n</em> = 33), HER2+ (<em>n</em> = 12) and TNBC (<em>n</em> = 24) subtypes were 8.0 (3.02, 24.8), 5.71 (1.61, not estimated) and 3.2 (1.11, 4.95) months (<em>P</em> = .17). In multivariate analysis, TNBC was associated with worse OS versus ER+/HER2- [Hazard Ratio (HR), 95% CI: 2.64, 1.23-5.80, <em>P</em> = .04]. HER2 subtypes (HER2-Zero, <em>n</em> = 21; HER2-Low, <em>n</em> = 32; HER2+, <em>n</em> = 12) showed no significant differences in OS. Median OS (95% CI) for CSF+ (<em>n</em> = 16), CSF- (<em>n</em> = 18), and CSF NT (<em>n</em> = 35) groups were 3.54 (1.61, 12.72), 13.41 (4.95, 61.93) and 3.28 (1.44, 6.92) months (<em>P</em> = .04). Multivariate analysis showed both CSF+ and CSF NT were associated with shorter OS compared to CSF- group [HR (95% CI) 4.50 (1.75, 12.11) for CSF+ vs. CSF-; 2.91 (1.45, 6.26) for CSF NT vs. CSF-; <em>P</em> = .002].</div></div><div><h3>Conclusion</h3><div>TNBC LMD group was associated with worse OS than ER+/HER2- BC LMD when adjusting for other prognostic factors. CSF- LMD patients had better OS than CSF+ or CSF NT LMD.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 65-74.e5"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engaging Multidisciplinary Teams to Develop Pragmatic Clinical Practice Guidelines to Support Management of Patients With High-Risk Breast Lesions","authors":"Heather B. Neuman ,&nbsp;Lee G. Wilke ,&nbsp;Laura M. Bozzuto ,&nbsp;Lacey Stelle ,&nbsp;David Melnick ,&nbsp;Mai Elezaby ,&nbsp;Ryan W. Woods ,&nbsp;Peter Chase ,&nbsp;Stephanie McGregor ,&nbsp;Jo Harter ,&nbsp;Paul Weissman ,&nbsp;Caprice C. Greenberg ,&nbsp;Elizabeth Burnside ,&nbsp;Amy M. Fowler ,&nbsp;Wendy B. DeMartini ,&nbsp;Lonie R. Salkowski ,&nbsp;Roberta M. Strigel","doi":"10.1016/j.clbc.2024.10.003","DOIUrl":"10.1016/j.clbc.2024.10.003","url":null,"abstract":"<div><h3>Introduction</h3><div>We sought to develop clinical guidelines within our multidisciplinary Breast Center to support decision-making for managing high-risk breast lesions. The objective is to describe the process used to develop these guidelines and assess perceived acceptability.</div></div><div><h3>Methods</h3><div>We recruited clinical stakeholders to identify key “high-risk” topics. Stakeholder groups (surgery, radiology, pathology) met separately to review the topics, leveraging existing literature reviews and best available evidence. Guidelines were initially developed in 2015 and updated in 2019. We surveyed breast clinical team members in 2023 regarding the perceived acceptability of the guidelines and summarized the data.</div></div><div><h3>Results</h3><div>We created clinical guidelines to address the management of atypical ductal hyperplasia, flat epithelial atypia, atypical lobular hyperplasia/lobular carcinoma in situ, radial scar/complex sclerosing lesion, and papillomas. Key guideline components included process for radiologic-pathologic correlation, patient disposition after biopsy (surgical referral needed, follow-up imaging recommended), recommendation for the role of surgical excision, and recommendation regarding imaging follow-up if excision not performed. Forty clinical team members (66% [40/60] response rate) completed the acceptability survey from varied disciplines. Most (78%) were aware of the guidelines. Respondents rated the recommendations for disposition after biopsy, surgical management, and follow-up imaging as the most helpful components. Most (&gt; 80%) rated them to be very/extremely useful.</div></div><div><h3>Conclusion</h3><div>We leveraged input from key stakeholders to develop clinical guidelines to support the multidisciplinary management of patients with high-risk breast lesions. Our guidelines have been successfully implemented across our academic and community practice. Future steps will assess the impact of implementation on clinical outcomes.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 56-64"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Patient Flap Management After Mastectomy: A Best Practice Implementation Project","authors":"Minshan Liang ,&nbsp;Yuanzhen Luo ,&nbsp;Xiaojun Wang ,&nbsp;Chunhua Chen ,&nbsp;Piao Chen ,&nbsp;Zhenchong Xiong ,&nbsp;Li Liu ,&nbsp;Mengxiao Jiang ,&nbsp;Huiting Zhang","doi":"10.1016/j.clbc.2024.09.004","DOIUrl":"10.1016/j.clbc.2024.09.004","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is a prevalent malignancy in women, with mastectomy as the main surgery. Common postmastectomy complications are seroma (15%-81%), infections (2.9%-3.8%), and flap necrosis (10%-18%), severely impacting quality of life and costs. However, there's a lack of standardized flap care protocols and limited staff knowledge.</div></div><div><h3>Objectives</h3><div>This study aims to apply best evidence for flap management post-mastectomy to standardize practices, reduce complications, and enhance patient's quality of life.</div></div><div><h3>Methods</h3><div>This project followed JBI PACES and GRiP principles, implementing evidence-based practices in a Chinese tertiary hospital between January and May 2023. It entailed evidence identification, integration into clinical context, protocol development, baseline audits, barrier/enabler analysis. The study compared pre- and post-evidence implementation rates of flap complications, healthcare staff's knowledge/skill scores on mastectomy flap management, and audit indicator adherence by both staff and patients.</div></div><div><h3>Results</h3><div>After evidence application, flap ischemia/necrosis rates dropped from 8.57% to 5.56% (<em>P</em> &lt; .001), wound infection rates after surgery reduced from 5.71% to 2.78% (<em>P</em> &lt; .001), and seroma rates decreased from 17.14% to 2.78% (<em>P</em> &lt; .001). Healthcare staff's knowledge and skill scores for flap management following mastectomy increased from 50.67 ±18.32 preimplementation to 98.33 ± 4.01 (<em>t</em> = -13.90, <em>P</em> &lt; .001). Audit criterion compliance rates increased from 8.57% to 94.29% to between 91.67% and 100%, with statistically significant differences in all 15 criteria (<em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>Evidence-based management of flaps after mastectomy improves healthcare staff's knowledge and skills, enhances nursing quality, effectively reduces flap complications in patients, and boosts their quality of life.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages 46-55"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric Diagnoses and Their Treatment in Women With Breast Cancer: A Latent Class Analysis of 1062 Inpatients","authors":"Jan Ben Schulze ,&nbsp;Marc Dörner ,&nbsp;Mona Huber ,&nbsp;Katja-Daniela Jordan ,&nbsp;Roland von Känel ,&nbsp;Sebastian Euler","doi":"10.1016/j.clbc.2024.06.011","DOIUrl":"10.1016/j.clbc.2024.06.011","url":null,"abstract":"<div><h3>Introduction</h3><div>Psycho-oncological support (POS) and psychopharmacological interventions are effective in treating psychiatric symptoms in patients with breast cancer. However, despite high prevalences of psychiatric disorders in patients with breast cancer, a significant proportion remains untreated.</div></div><div><h3>Methods</h3><div>Data from 1062 breast cancer patients who had been diagnosed and treated at a Comprehensive Cancer Center between 2012 and 2019 were analyzed retrospectively. We descriptively evaluated the number of patients with a psychiatric diagnosis, POS and psychiatric medication. Latent class analysis was used to examine the relationship between ICD-10 coded psychiatric diagnoses, POS, psychiatric medication, and, as important prognostic factors, tumor stage and somatic comorbidity.</div></div><div><h3>Results</h3><div>31.5% of all patients had a psychiatric diagnosis, 20% received POS and up to 60% received psychiatric medication. Latent class analysis revealed three subgroups: 1) patients with a low cancer stage, low somatic comorbidity, no psychiatric diagnosis, no POS and no psychiatric medication; 2) patients with a low cancer stage, low somatic comorbidity, a psychiatric diagnosis, and a higher probability of POS and psychiatric medication than class 1 and class 3; 3) patients with advanced cancer stage, high somatic comorbidity, a higher probability of a psychiatric diagnosis and POS than class 1, and no psychiatric medication.</div></div><div><h3>Conclusion</h3><div>This study indicated a high prevalence of psychiatric disorders among patients with breast cancer and a discrepancy between the number of patients having a psychiatric disorder and those receiving psychiatric medication. The identification of subgroups might contribute to better tailored treatment for those patients whose needs are insufficiently met.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 1","pages":"Pages e22-e29"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141574918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}